Market capitalization | $97.70m |
Enterprise Value | $138.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 163.32 |
EV/Sales (TTM) EV/Sales | 1.42 |
P/S ratio (TTM) P/S ratio | 1.00 |
P/B ratio (TTM) P/B ratio | 1.50 |
Revenue growth (TTM) Revenue growth | -13.15% |
Revenue (TTM) Revenue | $97.73m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Harvard Bioscience, Inc. forecast:
2 Analysts have issued a Harvard Bioscience, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 98 98 |
13%
13%
|
|
Gross Profit | 52 52 |
14%
14%
|
|
EBITDA | 2.49 2.49 |
72%
72%
|
EBIT (Operating Income) EBIT | -4.55 -4.55 |
377%
377%
|
Net Profit | -14 -14 |
337%
337%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
Head office | United States |
CEO | James Green |
Employees | 416 |
Founded | 1901 |
Website | www.harvardbioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.